TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Arshad M KhananiAachal KotechaAndrew ChangShih-Jen ChenYouxin ChenRobyn GuymerJeffrey S HeierFrank G HolzTomohiro IidaJane A IvesJennifer I LimHugh LinStephan MichelsCarlos Quezada RuizUrsula Schmidt-ErfurthDavid SilvermanRishi SinghBalakumar SwaminathanJeffrey R WillisRamin Tadayoninull nullPublished in: Ophthalmology (2024)
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.